Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. [electronic resource]
Producer: 20050513Description: 3303-11 p. digitalISSN:- 0006-4971
- Animals
- Antineoplastic Agents -- pharmacology
- Benzamides
- Cell Survival -- physiology
- DNA-Binding Proteins -- metabolism
- Down-Regulation
- Extracellular Signal-Regulated MAP Kinases -- metabolism
- Fusion Proteins, bcr-abl -- genetics
- Gene Expression Regulation, Leukemic -- drug effects
- Humans
- Imatinib Mesylate
- In Vitro Techniques
- K562 Cells
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- MAP Kinase Kinase Kinases -- metabolism
- Milk Proteins -- metabolism
- Myeloid Cell Leukemia Sequence 1 Protein
- Neoplasm Proteins -- genetics
- Oligonucleotides, Antisense -- pharmacology
- Piperazines -- pharmacology
- Proto-Oncogene Proteins c-bcl-2 -- genetics
- Pyrimidines -- pharmacology
- RNA, Small Interfering -- pharmacology
- STAT5 Transcription Factor
- Trans-Activators -- metabolism
- Tumor Cells, Cultured
- raf Kinases -- metabolism
- ras Proteins -- metabolism
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.